{
    "root": "95fe5aae-fad7-4794-aa62-dad9b2753080",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamotrigine",
    "value": "20240206",
    "ingredients": [
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6367"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)",
            "code": "5KY68S2577",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "TRICAPRIN",
            "code": "O1PB8EU98M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77388"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_78913"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_181906"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "lamotrigine extended-release tablets indicated : adjunctive therapy primary generalized tonic-clonic seizures partial-onset seizures without secondary generalization patients aged 13 years older . ( 1.1 ) conversion monotherapy patients aged 13 years older partial-onset seizures receiving treatment single antiepileptic . ( 1.2 ) limitation : safety effectiveness patients younger 13 years established . ( 1.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lamotrigine extended-release tablets taken daily , without food . tablets must swallowed whole must chewed , crushed , divided .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "lamotrigine extended-release tablets , usp 25 mg - white off-white , round , unscored , film-coated tablet imprinted one side 410 side contains 25 mg lamotrigine , usp . tablets supplied bottles 30 tablets ( ndc 0228-1410-03 ) . 50 mg - gray , round , unscored , film-coated tablet imprinted one side 435 side contains 50 mg lamotrigine , usp . tablets supplied bottles 30 tablets ( ndc 0228-1435-03 ) . 100 mg - gray , round , unscored , film-coated tablet imprinted one side 422 side contains 100 mg lamotrigine , usp . tablets supplied bottles 30 tablets ( ndc 0228-1422-03 ) . 200 mg - white off-white , round , unscored , film-coated tablet imprinted one side 453 side contains 200 mg lamotrigine , usp . tablets supplied bottles 30 tablets ( ndc 0228-1453-03 ) . 250 mg - yellow , capsule-shaped , unscored , film-coated tablet imprinted one side 638 side contains 250 mg lamotrigine , usp . tablets supplied bottles 30 tablets ( ndc 0228-1638-03 ) . 300 mg - gray , capsule-shaped , unscored , film-coated tablet imprinted one side 580 side contains 300 mg lamotrigine , usp . tablets supplied bottles 30 tablets ( ndc 0228-1580-03 ) . storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp .",
    "adverseReactions": "lamotrigine extended-release tablets contraindicated patients demonstrated hypersensitivity ( e.g . , rash , angioedema , acute urticaria , extensive pruritus , mucosal ulceration ) ingredients [ boxed warning , ( 5.1 , 5.3 ) ] .",
    "indications_original": "Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. ( 1.1 ) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. ( 1.2 ) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ( 1.3 )",
    "contraindications_original": "Lamotrigine extended-release tablets are taken once daily, with or without food. Tablets must be swallowed whole and must not be chewed, crushed, or divided.",
    "warningsAndPrecautions_original": "Lamotrigine extended-release tablets, USP\u00a0\n                  \n                  25 mg - Each white to off-white, round, unscored, film-coated tablet imprinted with \u00a0on one side and 410 on the other side contains 25 mg of lamotrigine, USP. Tablets are supplied in bottles of 30 tablets (NDC 0228-1410-03).\n                  50 mg - Each gray, round, unscored, film-coated tablet imprinted with \u00a0on one side and 435 on the other side contains 50 mg of lamotrigine, USP. Tablets are supplied in bottles of 30 tablets (NDC 0228-1435-03).\n                  100 mg - Each gray, round, unscored, film-coated tablet imprinted with \u00a0on one side and 422 on the other side contains 100 mg of lamotrigine, USP. Tablets are supplied in bottles of 30 tablets (NDC 0228-1422-03).\n                  200 mg - Each white to off-white, round, unscored, film-coated tablet imprinted with  on one side and 453 on the other side contains 200 mg of lamotrigine, USP. Tablets are supplied in bottles of 30 tablets (NDC 0228-1453-03).\n                  250 mg - Each yellow, capsule-shaped, unscored, film-coated tablet imprinted with \u00a0on one side and 638 on the other side contains 250 mg of lamotrigine, USP. Tablets are supplied in bottles of 30 tablets (NDC 0228-1638-03).\n                  300 mg - Each gray, capsule-shaped, unscored, film-coated tablet imprinted with \u00a0on one side and 580 on the other side contains 300 mg of lamotrigine, USP. Tablets are supplied in bottles of 30 tablets (NDC 0228-1580-03).\n                  \n                     Storage\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP.",
    "adverseReactions_original": "Lamotrigine extended-release tablets are contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see Boxed Warning, Warnings and Precautions (5.1, 5.3)].",
    "drug": [
        {
            "name": "Lamotrigine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6367"
        }
    ]
}